Literature DB >> 7524836

T cell recognition of haptens, a molecular view.

S Martin1, H U Weltzien.   

Abstract

Our review attempts to summarize the present knowledge on how T lymphocytes recognize chemically modified autologous cells. Concerning the broad spectrum of chemically and drug-induced allergic and autoimmune diseases, the molecular mechanisms of hapten recognition by T cells are clearly of more than academic interest. The past few years revealed that in contrast to the expectations of many researchers, major histocompatibility complex (MHC)-restricted hapten-specific T cell receptors in their majority do not react to covalently modified MHC molecules, but to haptenized peptides associated with the MHC peptide-binding groove. This finding allowed the introduction of synthetic hapten-peptide conjugates, the MHC specificity of which may be predetermined by allele-specific peptide sequence motifs. Thus, it has now become feasible to selectively hapten-modify defined sets of MHC molecules on living cells, and to study their immunological properties. In that way two major types of hapten-specific T cell receptors were identified: one reacting to hapten without caring for the chemical composition of the carrier peptide, and the other contacting hapten and peptide by two apparently independent contact sites. The consequences of these findings for hapten-specific allergies and autoimmunities, but also for our molecular understanding of antigen recognition by T cells are discussed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7524836     DOI: 10.1159/000236703

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  21 in total

Review 1.  Allergic reactions to drugs: involvement of T cells.

Authors:  W J Pichler; N Yawalkar
Journal:  Thorax       Date:  2000-10       Impact factor: 9.139

2.  [Allergic contact dermatitis to common ivy (Hedera helix L.)].

Authors:  C Ozdemir; L A Schneider; R Hinrichs; G Staib; L Weber; J M Weiss; K Scharffetter-Kochanek
Journal:  Hautarzt       Date:  2003-10       Impact factor: 0.751

3.  4D-fingerprint categorical QSAR models for skin sensitization based on the classification of local lymph node assay measures.

Authors:  Yi Li; Yufeng J Tseng; Dahua Pan; Jianzhong Liu; Petra S Kern; G Frank Gerberick; Anton J Hopfinger
Journal:  Chem Res Toxicol       Date:  2007-01       Impact factor: 3.739

4.  Immunostimulatory activity of haptenated proteins.

Authors:  Noah W Palm; Ruslan Medzhitov
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-02       Impact factor: 11.205

5.  Clonal expansion of T lymphocytes in human melanoma metastases after treatment with a hapten-modified autologous tumor vaccine.

Authors:  M Sensi; C Farina; C Maccalli; R Lupetti; G Nicolini; A Anichini; G Parmiani; D Berd
Journal:  J Clin Invest       Date:  1997-02-15       Impact factor: 14.808

Review 6.  Delayed drug hypersensitivity: models of T-cell stimulation.

Authors:  Jacqueline Adam; Werner J Pichler; Daniel Yerly
Journal:  Br J Clin Pharmacol       Date:  2011-05       Impact factor: 4.335

Review 7.  Cell and molecular biology of chemical allergy.

Authors:  I Kimber; R J Dearman
Journal:  Clin Rev Allergy Immunol       Date:  1997       Impact factor: 8.667

8.  T-cell involvement in drug-induced acute generalized exanthematous pustulosis.

Authors:  M Britschgi; U C Steiner; S Schmid; J P Depta; G Senti; A Bircher; C Burkhart; N Yawalkar; W J Pichler
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

9.  The murine buccal mucosa is an inductive site for priming class I-restricted CD8+ effector T cells in vivo.

Authors:  C Desvignes; F Estèves; N Etchart; C Bella; C Czerkinsky; D Kaiserlian
Journal:  Clin Exp Immunol       Date:  1998-09       Impact factor: 4.330

Review 10.  Beryllium-Induced Hypersensitivity: Genetic Susceptibility and Neoantigen Generation.

Authors:  Andrew P Fontenot; Michael T Falta; John W Kappler; Shaodong Dai; Amy S McKee
Journal:  J Immunol       Date:  2016-01-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.